Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Jabil Inc (JBL) vs Johnson & Johnson (JNJ) Price & Performance

Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

Jabil Inc vs Johnson & Johnson — how do they compare? Jabil Inc trades at $365.18 (market cap $37.37B), while Johnson & Johnson trades at $260.51 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 16.8× Jabil Inc's market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.

JBLJNJ
Market Cap
$37.37B$626.09B
Sector
TechnologyHealth
52-Week High
$385.50$267.24
52-Week Low
$192.49$172.78
Enterprise Value
$39.90B$654.37B
Dividend Yield
0.09%2.06%
Volume
6,156,228

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Jabil Inc

JBL stock trades at $366.16, up 8.77% in the last session, reflecting strong momentum driven by AI infrastructure demand. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.16 exceeding the $3.10 forecast. Technical indicators show a bullish trend with the stock approaching resistance near $371, while fundamentals reveal solid revenue growth projections from $29.8B in 2025 to $33.6B in 2026.

JBL presents compelling growth potential as an AI infrastructure play with projected revenue exceeding $20B by 2027, though elevated P/E of 44.63 and thin net margins of 2.57% warrant caution. Analyst consensus targets $448.29 (22% upside) with balanced buy/hold ratings. Key risks include execution challenges in scaling AI operations and competitive pressures in electronics manufacturing services.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.

Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Jabil Inc

Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.

Read more on JBL

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ